ParkinsonFranceV1, PubMed, Corpus, bibRecord, 000920

Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.

Identifieur interne : 000920 ( PubMed/Corpus ); précédent : 000919; suivant : 000921

Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.

Auteurs : Philippe Corcia ; Paul H. Gordon

Source :

Therapeutics and clinical risk management [ 1178-203X ] ; 2012.

RBID : pubmed:22956874

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that leads to progressive weakness from loss of motor neurons and death on average in less than 3 years after symptom onset. No clear causes have been found and just one medication, riluzole, extends survival. Researchers have identified some of the cellular processes that occur after disease onset, including mitochondrial dysfunction, protein aggregation, oxidative stress, excitotoxicity, inflammation, and apoptosis. Mitochondrial disease may be a primary event in neurodegeneration or occur secondary to other cellular processes, and may itself contribute to oxidative stress, excitotoxicity, and apoptosis. Clinical trials currently aim to slow disease progression by testing drugs that impact one or more of these pathways. While every agent tested in the 18 years after the approval of riluzole has been ineffective, basic and clinical research methods in ALS have become dramatically more sophisticated. Dexpramipexole (RPPX), the R(+) enantiomer of pramiprexole, which is approved for symptomatic treatment of Parkinson disease, carries perhaps the currently largest body of pre-and early clinical data that support testing in ALS. The neuroprotective properties of RPPX in various models of neurodegeneration, including the ALS murine model, may be produced through protective actions on mitochondria. Early phase trials in human ALS suggest that the drug can be taken safely by patients in doses that provide neuroprotection in preclinical models. A Phase III trial to test the efficacy of RPPX in ALS is underway.

DOI: 10.2147/TCRM.S21981
PubMed: 22956874

Links to Exploration step

pubmed:22956874

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.</title>
<author><name sortKey="Corcia, Philippe" sort="Corcia, Philippe" uniqKey="Corcia P" first="Philippe" last="Corcia">Philippe Corcia</name>
<affiliation><nlm:affiliation>Centre SLA, CHRU de Tours, Tours, France; UMR INSERM U930, Université François Rabelais de Tours (PC), Tours, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gordon, Paul H" sort="Gordon, Paul H" uniqKey="Gordon P" first="Paul H" last="Gordon">Paul H. Gordon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22956874</idno>
<idno type="pmid">22956874</idno>
<idno type="doi">10.2147/TCRM.S21981</idno>
<idno type="wicri:Area/PubMed/Corpus">000920</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000920</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.</title>
<author><name sortKey="Corcia, Philippe" sort="Corcia, Philippe" uniqKey="Corcia P" first="Philippe" last="Corcia">Philippe Corcia</name>
<affiliation><nlm:affiliation>Centre SLA, CHRU de Tours, Tours, France; UMR INSERM U930, Université François Rabelais de Tours (PC), Tours, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gordon, Paul H" sort="Gordon, Paul H" uniqKey="Gordon P" first="Paul H" last="Gordon">Paul H. Gordon</name>
</author>
</analytic>
<series><title level="j">Therapeutics and clinical risk management</title>
<idno type="eISSN">1178-203X</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that leads to progressive weakness from loss of motor neurons and death on average in less than 3 years after symptom onset. No clear causes have been found and just one medication, riluzole, extends survival. Researchers have identified some of the cellular processes that occur after disease onset, including mitochondrial dysfunction, protein aggregation, oxidative stress, excitotoxicity, inflammation, and apoptosis. Mitochondrial disease may be a primary event in neurodegeneration or occur secondary to other cellular processes, and may itself contribute to oxidative stress, excitotoxicity, and apoptosis. Clinical trials currently aim to slow disease progression by testing drugs that impact one or more of these pathways. While every agent tested in the 18 years after the approval of riluzole has been ineffective, basic and clinical research methods in ALS have become dramatically more sophisticated. Dexpramipexole (RPPX), the R(+) enantiomer of pramiprexole, which is approved for symptomatic treatment of Parkinson disease, carries perhaps the currently largest body of pre-and early clinical data that support testing in ALS. The neuroprotective properties of RPPX in various models of neurodegeneration, including the ALS murine model, may be produced through protective actions on mitochondria. Early phase trials in human ALS suggest that the drug can be taken safely by patients in doses that provide neuroprotection in preclinical models. A Phase III trial to test the efficacy of RPPX in ALS is underway.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22956874</PMID>
<DateCreated><Year>2012</Year>
<Month>09</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted><Year>2012</Year>
<Month>09</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>05</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1178-203X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>8</Volume>
<PubDate><Year>2012</Year>
</PubDate>
</JournalIssue>
<Title>Therapeutics and clinical risk management</Title>
<ISOAbbreviation>Ther Clin Risk Manag</ISOAbbreviation>
</Journal>
<ArticleTitle>Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.</ArticleTitle>
<Pagination><MedlinePgn>359-66</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2147/TCRM.S21981</ELocationID>
<Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that leads to progressive weakness from loss of motor neurons and death on average in less than 3 years after symptom onset. No clear causes have been found and just one medication, riluzole, extends survival. Researchers have identified some of the cellular processes that occur after disease onset, including mitochondrial dysfunction, protein aggregation, oxidative stress, excitotoxicity, inflammation, and apoptosis. Mitochondrial disease may be a primary event in neurodegeneration or occur secondary to other cellular processes, and may itself contribute to oxidative stress, excitotoxicity, and apoptosis. Clinical trials currently aim to slow disease progression by testing drugs that impact one or more of these pathways. While every agent tested in the 18 years after the approval of riluzole has been ineffective, basic and clinical research methods in ALS have become dramatically more sophisticated. Dexpramipexole (RPPX), the R(+) enantiomer of pramiprexole, which is approved for symptomatic treatment of Parkinson disease, carries perhaps the currently largest body of pre-and early clinical data that support testing in ALS. The neuroprotective properties of RPPX in various models of neurodegeneration, including the ALS murine model, may be produced through protective actions on mitochondria. Early phase trials in human ALS suggest that the drug can be taken safely by patients in doses that provide neuroprotection in preclinical models. A Phase III trial to test the efficacy of RPPX in ALS is underway.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corcia</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Centre SLA, CHRU de Tours, Tours, France; UMR INSERM U930, Université François Rabelais de Tours (PC), Tours, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gordon</LastName>
<ForeName>Paul H</ForeName>
<Initials>PH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>08</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Ther Clin Risk Manag</MedlineTA>
<NlmUniqueID>101253281</NlmUniqueID>
<ISSNLinking>1176-6336</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Mar 14;66(5):660-3</RefSource>
<PMID Version="1">16534103</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):948-50</RefSource>
<PMID Version="1">16614011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2006 Jul;60(1):22-31</RefSource>
<PMID Version="1">16802291</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Nov 28;67(10):1748-51</RefSource>
<PMID Version="1">17130405</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Jan 9;68(2):141-5</RefSource>
<PMID Version="1">17210896</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Jan 30;68(5):326-37</RefSource>
<PMID Version="1">17261678</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2007 Dec;6(12):1045-53</RefSource>
<PMID Version="1">17980667</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):6-11</RefSource>
<PMID Version="1">18079297</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neurophysiol. 2008 Mar;119(3):497-503</RefSource>
<PMID Version="1">18164242</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2052-7</RefSource>
<PMID Version="1">18250315</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2008 Aug;212(2):522-31</RefSource>
<PMID Version="1">18571649</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler. 2008 Aug;9(4):212-22</RefSource>
<PMID Version="1">18608093</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 Jan;65 Suppl 1:S3-9</RefSource>
<PMID Version="1">19191304</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Orphanet J Rare Dis. 2009;4:3</RefSource>
<PMID Version="1">19192301</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Feb 24;72(8):725-31</RefSource>
<PMID Version="1">19237701</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler. 2009 Aug;10(4):216-20</RefSource>
<PMID Version="1">19452307</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Neurol. 2009 Jun;16(6):745-51</RefSource>
<PMID Version="1">19475756</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2009 Jun;66(6):758-61</RefSource>
<PMID Version="1">19506136</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2010 Jan;1802(1):45-51</RefSource>
<PMID Version="1">19715760</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Sep 8;73(10):805-11</RefSource>
<PMID Version="1">19738176</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):378-83</RefSource>
<PMID Version="1">19922128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler. 2010 Aug;11(4):379-82</RefSource>
<PMID Version="1">20001486</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Pharmacol. 2010;10:2</RefSource>
<PMID Version="1">20137065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler. 2010;11(1-2):38-45</RefSource>
<PMID Version="1">20184514</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2010 May;9(5):481-8</RefSource>
<PMID Version="1">20363190</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler. 2010 Dec;11(6):497-501</RefSource>
<PMID Version="1">20536375</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Aug 17;75(7):619-25</RefSource>
<PMID Version="1">20702794</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2011 Aug;51(8):1177-85</RefSource>
<PMID Version="1">20959524</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>IDrugs. 2010 Dec;13(12):911-20</RefSource>
<PMID Version="1">21154151</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler. 2011 Sep;12(5):372-8</RefSource>
<PMID Version="1">21585273</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2011 Sep 6;77(10):973-9</RefSource>
<PMID Version="1">21813790</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurol. 2011 Nov;7(11):650-4</RefSource>
<PMID Version="1">21947135</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurol. 2011 Nov;7(11):603-15</RefSource>
<PMID Version="1">21989245</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2011 Dec;17(12):1652-6</RefSource>
<PMID Version="1">22101764</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Expert Opin Investig Drugs. 2012 Mar;21(3):297-320</RefSource>
<PMID Version="1">22303913</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2012 Mar 29;1446:1-11</RefSource>
<PMID Version="1">22364637</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2012 Sep;342(3):619-30</RefSource>
<PMID Version="1">22700435</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler. 2012 Oct;13(6):585-8</RefSource>
<PMID Version="1">22873563</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2012;3:CD001447</RefSource>
<PMID Version="1">22419278</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1997 Apr 18;754(1-2):181-6</RefSource>
<PMID Version="1">9134974</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 2007 Feb 28;557(2-3):132-40</RefSource>
<PMID Version="1">17161393</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler. 2008 Feb;9(1):50-8</RefSource>
<PMID Version="1">18270879</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CNS Neurosci Ther. 2008 Fall;14(3):215-26</RefSource>
<PMID Version="1">18801114</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Med Res Opin. 2009 Dec;25(12):2977-87</RefSource>
<PMID Version="1">19842998</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1991 Jun;48(6):589-93</RefSource>
<PMID Version="1">2039380</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1966 May;16(5):475-81</RefSource>
<PMID Version="1">5949060</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 1994 Jun 17;264(5166):1772-5</RefSource>
<PMID Version="1">8209258</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1993 Dec;61(6):2322-5</RefSource>
<PMID Version="1">8245985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1994 Mar 3;330(9):585-91</RefSource>
<PMID Version="1">8302340</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1996 May 25;347(9013):1425-31</RefSource>
<PMID Version="1">8676624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Opin Neurobiol. 1996 Oct;6(5):679-87</RefSource>
<PMID Version="1">8937834</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1996 Dec 2;742(1-2):80-8</RefSource>
<PMID Version="1">9117424</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1997 May 9;756(1-2):247-55</RefSource>
<PMID Version="1">9187339</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1997 Sep;49(3):724-8</RefSource>
<PMID Version="1">9305331</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1998 Jul;71(1):295-301</RefSource>
<PMID Version="1">9648878</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1999 Sep 22;53(5):1123-5</RefSource>
<PMID Version="1">10496278</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2000 Jan;57(1):109-13</RefSource>
<PMID Version="1">10634456</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2000 Jan 15;151(2):156-63</RefSource>
<PMID Version="1">10645818</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Apr 10;56(7):843-8</RefSource>
<PMID Version="1">11294919</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Muscle Nerve. 2001 Mar;24(3):403-9</RefSource>
<PMID Version="1">11353427</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2001 May 31;344(22):1688-700</RefSource>
<PMID Version="1">11386269</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2001 Jun 29;905(1-2):44-53</RefSource>
<PMID Version="1">11423078</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9</RefSource>
<PMID Version="1">11464847</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci Res. 2002 Feb 15;67(4):494-500</RefSource>
<PMID Version="1">11835316</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurochem Int. 2002 May;40(6):543-51</RefSource>
<PMID Version="1">11850111</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Aug 26;61(4):456-64</RefSource>
<PMID Version="1">12939417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Jun;4(2):90-5</RefSource>
<PMID Version="1">14506939</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2003 Dec;74 Suppl 4:iv32-iv47</RefSource>
<PMID Version="1">14645465</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Jun;5(2):107-17</RefSource>
<PMID Version="1">15204012</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2004 Dec;91(5):1075-81</RefSource>
<PMID Version="1">15569251</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 Aug 23;65(4):586-90</RefSource>
<PMID Version="1">16116120</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2006 Jan;316(1):189-99</RefSource>
<PMID Version="1">16188953</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):257-66</RefSource>
<PMID Version="1">16362428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2006 Mar;20(3):556-8</RefSource>
<PMID Version="1">16407457</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2006 Feb;5(2):140-7</RefSource>
<PMID Version="1">16426990</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Expert Opin Pharmacother. 2006 Mar;7(4):441-51</RefSource>
<PMID Version="1">16503816</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<OtherID Source="NLM">PMC3431958</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword>
<Keyword MajorTopicYN="N">clinical trials</Keyword>
<Keyword MajorTopicYN="N">dexpramipexole</Keyword>
<Keyword MajorTopicYN="N">neurodegeneration</Keyword>
<Keyword MajorTopicYN="N">survival</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>9</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>9</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>9</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22956874</ArticleId>
<ArticleId IdType="doi">10.2147/TCRM.S21981</ArticleId>
<ArticleId IdType="pii">tcrm-8-359</ArticleId>
<ArticleId IdType="pmc">PMC3431958</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000920 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000920 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:22956874
   |texte=   Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:22956874" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.

Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki